The Role of WNT5a and TGF-β1 in Airway Remodelling and Severe Asthma
Jan 3, 2025 · Airway remodelling is a feature of severe asthma with airway epithelial damage observed frequently. We evaluated the role of WNT5a and TGF-β 1 in asthmatic airway biopsies and in sputum and bronchial brushings assessed their role in remodelling.
Epithelial cell dysfunction, a major driver of asthma development
Analysis of matched single‐cell RNA‐Sequencing data sets from airway wall biopsies, bronchial brushes and nasal brushes will allow identification of novel biomarkers for disease activity or treatment response using less invasive methodologies.
Respiratory - GSK US
From uncontrolled asthma to severe eosinophilic asthma, we are committed to understanding the asthma community’s treatment needs. Visit asthma.com to learn more about the different types of asthma and the role eosinophils may play in severe eosinophilic asthma.
GSK announces positive results from phase III severe asthma trials …
May 21, 2024 · GSK plc (LSE/NYSE: GSK) today announced positive headline results from the phase III clinical trials SWIFT-1 and SWIFT-2, which assessed the efficacy and safety of depemokimab versus placebo in adults and adolescents with severe asthma with type 2 inflammation characterised by blood eosinophil count. 1,2 Both SWIFT-1 and SWIFT-2 …
Respiratory Therapeutic Area Information - Asthma - GSKpro
Discover respiratory conditions like asthma. Find educational resources about how to recognize asthma and tests that you can give to your patients.
The crosstalk between microbiome and asthma: Exploring …
Brush samples of asthmatic patients had higher abundance of Lactobacillus, Pseudomonas and Rickettsia species compared to controls, in contrast, healthy controls had higher abundance of Prevotella, Streptococcus and Veillonella. Relative abundances of bacterial taxa were significantly associated with corticosteroid use.
Phase III Trials Show Depemokimab Reduces Severe Asthma …
Jun 12, 2024 · Research has highlighted the need for simplified treatment regimens in severe asthma. A GSK-conducted survey revealed that 73% of physicians believe that longer dosing intervals could benefit patients managing multiple therapies. Khavandi echoed this sentiment, stating, “This six-month dosing schedule has the potential to address a key unmet ...
GSK’s twice-yearly asthma drug clears two phase 3 trials
Jan 20, 2025 · The company says new IL-5 inhibitor depemokimab (formerly GSK3511294) has the potential to become the first ultra-long-acting biologic for severe asthma with a six-monthly dosing schedule.
Asthma management: it’s time to get personal | GSK US
Asthma is a chronic lung disease characterized by inflammation and narrowing of the airways. This can lead to symptoms such as coughing, wheezing, breathlessness and chest tightness. When these symptoms become worse, it can lead to an asthma attack.
Real world effects of tezepelumab on small airways dysfunction in ...
2 days ago · Small airways dysfunction (SAD) involves narrowing of the airways < 2mm in calibre between generations 8 and 23 of the bronchial tree1. It can be defined using airway oscillometry (AO), an effort independent test which superimposes sound waves on top of tidal breathing. This in turn measures resistance (R) and reactance (X) components of respiratory impedance. Frequency dependent heterogeneity ...